MNPR
Monopar Therapeutics Inc.
Biotechnology
Market Cap$416M
5Y Perf.+186.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MNPR vs ADXN vs PRAX vs IQV
Revenue, margins, valuation, and 5-year total return — side by side.
ADXN
Addex Therapeutics Ltd
Biotechnology
Market Cap$5M
5Y Perf.-96.9%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$9.63B
5Y Perf.-37.1%
IQV
IQVIA Holdings Inc.
Medical - Diagnostics & Research
Market Cap$30.32B
5Y Perf.+16.1%
MNPR vs ADXN vs PRAX vs IQV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MNPR | ADXN | PRAX | IQV |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $416M | $5M | $9.63B | $30.32B |
| Revenue (TTM) | $0.00 | $68K | $-92K | $16.63B |
| Net Income (TTM) | $-19M | $-6M | $-327M | $1.39B |
| Gross Margin | — | -246.8% | — | 26.1% |
| Operating Margin | — | -36.7% | — | 13.9% |
| Forward P/E | — | 0.7x | — | 14.0x |
| Total Debt | $0.00 | $42K | $110K | $16.17B |
| Cash & Equiv. | $46M | $3M | $357M | $1.98B |
MNPR vs ADXN vs PRAX vs IQV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MNPR
ADXN
PRAX
IQV
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Monopar Therapeutic… (MNPR) | 100 | 286.4 | +186.4% |
| Addex Therapeutics … (ADXN) | 100 | 3.1 | -96.9% |
| Praxis Precision Me… (PRAX) | 100 | 62.9 | -37.1% |
| IQVIA Holdings Inc. (IQV) | 100 | 116.1 | +16.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MNPR vs ADXN vs PRAX vs IQV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ADXN and IQV are tied at the top with 2 categories each — the right choice depends on your priorities. IQVIA Holdings Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. MNPR and PRAX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
MNPR
Monopar Therapeutics Inc.
The Growth Leader
MNPR is the clearest fit if your priority is growth.
- 1.9K% revenue growth vs PRAX's -100.0%
Best for: growth
ADXN
Addex Therapeutics Ltd
The Income Pick
ADXN has the current edge in this matchup, primarily because of its strength in income & stability and sleep-well-at-night.
- beta 0.59
- Lower volatility, beta 0.59, Low D/E 0.4%, current ratio 4.42x
- Beta 0.59, current ratio 4.42x
- Lower P/E (0.7x vs 14.0x)
Best for: income & stability and sleep-well-at-night
PRAX
Praxis Precision Medicines, Inc.
The Momentum Pick
PRAX is the clearest fit if your priority is momentum.
- +7.7% vs ADXN's -13.1%
Best for: momentum
IQV
IQVIA Holdings Inc.
The Growth Play
IQV is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 5.9%, EPS growth 4.7%, 3Y rev CAGR 4.2%
- 166.5% 10Y total return vs PRAX's -20.1%
- 8.3% margin vs ADXN's -90.2%
- 4.7% ROA vs ADXN's -67.7%, ROIC 8.7% vs -103.3%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MNPR | 1.9K% revenue growth vs PRAX's -100.0% |
| Value | ADXN | Lower P/E (0.7x vs 14.0x) |
| Quality / Margins | IQV | 8.3% margin vs ADXN's -90.2% |
| Stability / Safety | ADXN | Beta 0.59 vs PRAX's 1.55 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PRAX | +7.7% vs ADXN's -13.1% |
| Efficiency (ROA) | IQV | 4.7% ROA vs ADXN's -67.7%, ROIC 8.7% vs -103.3% |
MNPR vs ADXN vs PRAX vs IQV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
FY 2024
FY 2025
MNPR vs ADXN vs PRAX vs IQV — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIQVLAGGINGADXN
Who Leads Where
IQV leads in 2 of 6 categories
PRAX leads 1 • MNPR leads 0 • ADXN leads 0 • 2 tied
Explore the data ↓ADXNAddex Therapeutics Ltd
0leads
MNPRMonopar Therapeutics …
0leads
PRAXPraxis Precision Medi…
1leads
IQVIQVIA Holdings Inc.
2leads
6 Total Categories
CATEGORYLEADERvs PRAXvs MNPRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
IQV6/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IQV6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
IQV leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
IQV and PRAX operate at a comparable scale, with $16.6B and -$92,000 in trailing revenue. IQV is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to ADXN's -90.2%. On growth, IQV holds the edge at +8.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $67,607 | -$92,000 | $16.6B |
| EBITDAEarnings before interest/tax | -$20M | -$2M | -$357M | $3.5B |
| Net IncomeAfter-tax profit | -$19M | -$6M | -$327M | $1.4B |
| Free Cash FlowCash after capex | -$11M | -$2M | -$283M | $2.7B |
| Gross MarginGross profit ÷ Revenue | — | -2.5% | — | +26.1% |
| Operating MarginEBIT ÷ Revenue | — | -36.7% | — | +13.9% |
| Net MarginNet income ÷ Revenue | — | -90.2% | — | +8.3% |
| FCF MarginFCF ÷ Revenue | — | -23.3% | — | +16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -44.8% | — | +8.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +11.2% | +2.7% | +15.0% |
IQV leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
Evenly matched — MNPR and ADXN and IQV each lead in 1 of 3 comparable metrics.
Valuation Metrics
At 0.7x trailing earnings, ADXN trades at a 97% valuation discount to IQV's 22.8x P/E.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Market CapShares × price | $416M | $5M | $9.6B | $30.3B |
| Enterprise ValueMkt cap + debt − cash | $370M | $394,716 | $9.3B | $44.5B |
| Trailing P/EPrice ÷ TTM EPS | -45.90x | 0.65x | -24.72x | 22.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 13.96x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.56x |
| EV / EBITDAEnterprise value multiple | — | — | — | 12.97x |
| Price / SalesMarket cap ÷ Revenue | — | 8.93x | — | 1.86x |
| Price / BookPrice ÷ Book value/share | 13.03x | 0.46x | 8.54x | 4.67x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 14.78x |
Evenly matched — MNPR and ADXN and IQV each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
IQV leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
IQV delivers a 22.1% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-78 for ADXN. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), MNPR scores 4/9 vs PRAX's 3/9, reflecting mixed financial health.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -25.7% | -78.3% | -43.0% | +22.1% |
| ROA (TTM)Return on assets | -24.8% | -67.7% | -40.2% | +4.7% |
| ROICReturn on invested capital | -3.2% | -103.3% | -65.0% | +8.7% |
| ROCEReturn on capital employed | -53.3% | -47.4% | -49.3% | +11.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 3 | 4 |
| Debt / EquityFinancial leverage | — | 0.00x | 0.00x | 2.44x |
| Net DebtTotal debt minus cash | -$46M | -$3M | -$357M | $14.2B |
| Cash & Equiv.Liquid assets | $46M | $3M | $357M | $2.0B |
| Total DebtShort + long-term debt | $0 | $41,994 | $110,000 | $16.2B |
| Interest CoverageEBIT ÷ Interest expense | — | -1857.72x | — | 3.10x |
IQV leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MNPR five years ago would be worth $23,648 today (with dividends reinvested), compared to $354 for ADXN. Over the past 12 months, PRAX leads with a +775.0% total return vs ADXN's -13.1%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs ADXN's -21.7% — a key indicator of consistent wealth creation.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.4% | -13.3% | +16.4% | -20.7% |
| 1-Year ReturnPast 12 months | +59.7% | -13.1% | +775.0% | +16.5% |
| 3-Year ReturnCumulative with dividends | +1148.6% | -52.0% | +1976.5% | -5.9% |
| 5-Year ReturnCumulative with dividends | +136.5% | -96.5% | -20.8% | -23.8% |
| 10-Year ReturnCumulative with dividends | -52.9% | -96.9% | -20.1% | +166.5% |
| CAGR (3Y)Annualised 3-year return | +132.0% | -21.7% | +174.9% | -2.0% |
PRAX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ADXN and PRAX each lead in 1 of 2 comparable metrics.
Risk & Volatility
ADXN is the less volatile stock with a 0.59 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs ADXN's 58.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.44x | 0.60x | 1.40x | 1.32x |
| 52-Week HighHighest price in past year | $105.00 | $12.05 | $356.00 | $247.05 |
| 52-Week LowLowest price in past year | $28.40 | $5.41 | $35.18 | $134.65 |
| % of 52W HighCurrent price vs 52-week peak | +59.5% | +58.2% | +93.6% | +72.3% |
| RSI (14)Momentum oscillator 0–100 | 68.1 | 51.3 | 55.6 | 58.5 |
| Avg Volume (50D)Average daily shares traded | 173K | 4K | 378K | 1.6M |
Evenly matched — ADXN and PRAX each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: MNPR as "Buy", PRAX as "Buy", IQV as "Buy". Consensus price targets imply 90.6% upside for MNPR (target: $119) vs 25.3% for IQV (target: $224).
| Metric | MNPRMonopar Therapeut… | ADXNAddex Therapeutic… | PRAXPraxis Precision … | IQVIQVIA Holdings In… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | $119.00 | — | $548.80 | $223.75 |
| # AnalystsCovering analysts | 13 | — | 16 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | 2 |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +4.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
IQV leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRAX leads in 1 (Total Returns). 2 tied.
Best OverallIQVIA Holdings Inc. (IQV)Leads 2 of 6 categories
Loading custom metrics...
MNPR vs ADXN vs PRAX vs IQV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is MNPR or ADXN or PRAX or IQV a better buy right now?
For growth investors, IQVIA Holdings Inc.
(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Addex Therapeutics Ltd (ADXN) offers the better valuation at 0. 7x trailing P/E, making it the more compelling value choice. Analysts rate Monopar Therapeutics Inc. (MNPR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MNPR or ADXN or PRAX or IQV?
On trailing P/E, Addex Therapeutics Ltd (ADXN) is the cheapest at 0.
7x versus IQVIA Holdings Inc. at 22. 8x.
03Which is the better long-term investment — MNPR or ADXN or PRAX or IQV?
Over the past 5 years, Monopar Therapeutics Inc.
(MNPR) delivered a total return of +136. 5%, compared to -96. 5% for Addex Therapeutics Ltd (ADXN). Over 10 years, the gap is even starker: IQV returned +166. 6% versus ADXN's -97. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MNPR or ADXN or PRAX or IQV?
By beta (market sensitivity over 5 years), Addex Therapeutics Ltd (ADXN) is the lower-risk stock at 0.
60β versus Monopar Therapeutics Inc. 's 1. 44β — meaning MNPR is approximately 141% more volatile than ADXN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — MNPR or ADXN or PRAX or IQV?
By revenue growth (latest reported year), IQVIA Holdings Inc.
(IQV) is pulling ahead at 5. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Addex Therapeutics Ltd grew EPS 150. 0% year-over-year, compared to -134. 5% for Monopar Therapeutics Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MNPR or ADXN or PRAX or IQV?
Addex Therapeutics Ltd (ADXN) is the more profitable company, earning 1746% net margin versus 0.
0% for Praxis Precision Medicines, Inc. — meaning it keeps 1746% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -681. 8% for ADXN. At the gross margin level — before operating expenses — ADXN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MNPR or ADXN or PRAX or IQV more undervalued right now?
Analyst consensus price targets imply the most upside for MNPR: 90.
6% to $119. 00.
08Which pays a better dividend — MNPR or ADXN or PRAX or IQV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is MNPR or ADXN or PRAX or IQV better for a retirement portfolio?
For long-horizon retirement investors, Addex Therapeutics Ltd (ADXN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
60)). Both have compounded well over 10 years (ADXN: -97. 0%, MNPR: -52. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MNPR and ADXN and PRAX and IQV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MNPR is a small-cap quality compounder stock; ADXN is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.